Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Market Cap	3.25B -5.6%
Revenue (ttm)	574.88M +17.9%
Net Income	156.70M +47.7%
EPS	0.94 +48.8%
Shares Out	166.80M
PE Ratio	20.70
Forward PE	14.20
Dividend	0.20 (1.09%)
Ex-Dividend Date	Jul 10, 2025

Volume	2,898,271
Average Volume	2,341,068
Open	18.42
Previous Close	18.46
Day's Range	18.36 - 19.58
52-Week Range	18.36 - 31.13
Beta	0.51
RSI	47.50
Earnings Date	Apr 23, 2026

About Cabio Biotech (Wuhan)

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 574
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688089

Financial Performance

In 2025, Cabio Biotech (Wuhan)'s revenue was 574.88 million, an increase of 3.47% compared to the previous year's 555.59 million. Earnings were 156.70 million, an increase of 26.15%.